Ganli Pharmaceutical: GZR102 injection Phase I clinical trial completed first subject dosing.

Ganzi Pharmaceutical announced that the Phase I clinical trial of GZR102 injection developed independently by the company has completed the first dose to the subject. GZR102 injection is a fixed-ratio compound preparation of basal insulin/GLP-1RA, which is expected to reduce the injection frequency, improve medication compliance, and enhance the quality of life for patients with type 2 diabetes while maintaining good safety and effectiveness. As of March 31, 2025, Ganzi Pharmaceutical has invested a total of 18.2481 million RMB in research and development expenses for the GZR102 injection project.